Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 34009-23-2191 | Other Grant/Funding Number | Green Development and Demonstration Programme (GUDP) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn whether daily intake of lactic acid bacteria fermented or unfermented legumes can improve metabolic and gut health in healthy adults.
The main questions it aims to answer are:
Participants will:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fermented pulses group 1 | Experimental | Participants will be instructed to consume 100 g of lactic acid fermented pulses daily as part of their usual diet. |
|
| Unfermented pulses group 2 | Experimental | Participants will be instructed to consume 100 g of unfermented pulses daily as part of their usual diet. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pulses meal study | Dietary Supplement | The participants are randomly assigned to two experimental groups based on a randomized trial design: two weeks of habitual dietary intake (control period) followed by the second intervention period lasts from day 14 to day 28, during which participants will be instructed to consume 100 g of lactic acid fermented pulses every day, seven days a week, for two weeks. Fermented pulses will be provided and packed as standardized food items to their habitual meals e.g. as hummus, or pasta with legume flour, adding up to 100 g of legumes per day. These test foods can be eaten throughout the day; however, intake of other legumes, except those included in the foods, should be avoided. |
| Measure | Description | Time Frame |
|---|---|---|
| Continuous glucose monitoring | Continuous Glucose Monitoring (CGM) will be measured in real-time and intermittently scanned CGM (isCGM) bi-weekly with an isCGM sensor (model Abbott Freestyle Libre PRO). This method is a minimally invasive method, as the sensor is placed on the participant's arm (26-30), by participants themselves after careful instructions, incl. videos. The Abbott Freestyle Libre PRO is blinded to the participants to avoid habitual changes, and it measures CGM in real-time throughout the entire 14-day period. The study follows the Standardized CGM metrics for Clinical Care, and the 14-day duration is aligned with the international recommendations (26,30). To ensure accurate and meaningful interpretation of CGM, adequate glucose data is collected according to the recommendation (70% of data from 14 days) (26,30). Data from participants with a CGM activity < 70% will be analyzed with the intention to treat principles. | From day zero to 14 days and from day 14 to day 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Inflammation CRP level | Fasting C-reactive proteins (CRP) monitoring will be measured at baseline, 14 days, and at day 28 by a finger prick test using a QuickRead go PLUS Instrument (#154580-4). | Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28). |
| Fasting Cholesterol |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tenna Mie Christoffersen, ph.D | Contact | +45 72482246 | tch@pha.dk | |
| Louise Almer, phD student | Contact | +45 72482258 | loua@pha.dk |
| Name | Affiliation | Role |
|---|---|---|
| Margit Dall Aaslyng, PhD | University College Absalon | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University College Absalon | Slagelse | 4200 | Denmark |
Data are person-centered and ethical commitee requires no sharing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 16, 2026 | Mar 24, 2026 | Prot_000.pdf |
Not provided
A parallel two-armed randomized trial. The participants are randomly assigned to two experimental groups based on a randomized trial design: two weeks of habitual dietary intake (control period), two weeks of LAB fermented foods, or two weeks of unfermented foods.
The control period is from zero to 14 days, and after these two weeks, baseline data will be collected from all subjects. The second intervention period lasts from day 14 to day 28, during which participants will be instructed to consume 100 g of either fermented or unfermented legumes every day, seven days a week, for two weeks.
Not provided
Not provided
Not possible to mask the intervention, as unfermented and fermented pulses are easy to see.
Not provided
|
| Pulses Meal Study | Dietary Supplement | The participants are randomly assigned to two experimental groups based on a randomized trial design: two weeks of habitual dietary intake (control period) followed by the second intervention period lasts from day 14 to day 28, during which participants will be instructed to consume 100 g of unfermented pulses every day, seven days a week, for two weeks. The unfermented pulses will be provided and packed as standardized food items to their habitual meals e.g. as hummus, or pasta with legume flour, adding up to 100 g of legumes per day. These test foods can be eaten throughout the day; however, intake of other legumes, except those included in the foods, should be avoided. |
|
Fasting cholesterol monitoring will be conducted at baseline, 14 days, and at day 28 by a finger prick test using a QuickRead go PLUS Instrument (#154580-4). |
| Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28). |
| Long-term blood glucose | Fasting hemoglobin A1c (HbA1c) monitoring will be conducted at baseline, 14 days, and at day 28 by a finger prick test using a QuickRead go PLUS Instrument (#154580-4). | Three measures; at baseline (day 0), follow up 1(day 14) and at follow up 2 (day 28). |
| Blood pressure | Systolic and diastolic blood pressures will be measured at baseline, day 14, and at day 28. Blood pressures will be measured in millimeters of mercury using an automatic blood pressure monitor (Digital Automatic Blood Pressure Monitor, Omron). Participants will be asked to lie down and relax for approximately 8 to 10 minutes, and 3 blood pressure measurements will be recorded at 5-minute intervals. | Three measurements; at baseline (day 0), follow up 1 (day 14) and at follow up 2 (day 28). |
| Body composition | Anthropometric measurements, will be measured by a Body Impedance Analytics (BIA) (TANITA MC 780 MA S, Japan). Height (m) will be measured using a standard dynamometer without shoes and is recorded to the nearest 0.1 cm. Body mass index (BMI) is calculated by dividing weight (kg) by height (m) squared (kg/m2). Waist and hip circumferences will be measured using a standardized tape measure that is calibrated before use. Waist circumference (cm) will be measured at the midpoint between the lowest rib and the upper part of the iliac bone in a standing position. Hip circumference (cm) will be measured at the site of the largest circumference between the waist and thighs. | Three measurements; at baseline (day 0), follow up 1 (day 14) and at follow up 2 (day 28). |
| Fecal sample | Fecal samples (approximately 10 g) will be collected from all participants. Participants are collecting the samples by themselves using the EasySampler tool kit, including a thorough written introduction(33,34). Fecal pH will be determined by mixing fecal matter 1:2 with sterile MilliQ-water after which pH is measured. Total fecal DNA will be extracted using standard methods. The gut microbial metagenome will be determined by shotgun high-throughput sequencing using long-read Oxford Nanopore-based sequencing. Before any further bioinformatics processing the raw reads will be purged of any human DNA-related sequences.. Fecal short chain fatty acids and other fecal metabolite concentrations, incl. free amino acids, are determined using high-field nuclear magnetic resonance NMR on fecal samples. | Three measurements: at baseline (day 0), follow up 1 (day 14), and at follow up 2 (day 28). |
| Dietary intake | Data on dietary intake will be collected by three-day dietary records with photos to evaluate adherence to the intervention. The dietary records will be collected once during the control period and once during the intervention period. Photos will be used for main meals and leftovers of legumes. Physical activity will also be documented as part of the dietary records and used to estimate energy expenditure. Furthermore, data on dietary intake will be used to assess compliance with the intervention. | Three measurements: at baseline (day 0), follow-up 1 (day 14) and follow-ip 2 (day 28). |
| Digestive abnormalities | Digestive abnormalities are identified through IBS symptoms and will be assessed using self-reported questionnaires using the IBS Severity Scoring System (IBS-SSS) for assessment of the following symptoms: abdominal distension, abdominal pain, satisfaction with bowel habits, and the extent to which symptoms affect the quality of life (QoL). | Three measurements: at baseline (day 0) , follow-up 1 (day 14), and at follow-up 2 (day 28). |